Dataset Information


Glycosuria and Renal Outcomes in Patients with Nondiabetic Advanced Chronic Kidney Disease.

ABSTRACT: Sodium glucose cotransporter 2 inhibitors have shown a potential for renoprotection beyond blood glucose lowering. Glycosuria in nondiabetic patients with chronic kidney disease (CKD) is sometimes noted. Whether glycosuria in CKD implies a channelopathy or proximal tubulopathy is not known. The consequence of glycosuria in CKD is also not studied. We performed a cross-sectional study for the association between glycosuria and urine electrolyte excretion in 208 nondiabetic patients. Fractional excretion (FE) of glucose >4% was 3.4%, 6.3% and 62.5% in CKD stage 3, 4 and 5, respectively. These patients with glycosuria had higher FE sodium, FE potassium, FE uric acid, UPCR, and urine NGAL-creatinine ratio. We conducted a longitudinal study for the consequence of glycosuria, defined by dipstick, in 769 nondiabetic patients with stage 4-5 CKD. Glycosuria was associated with a decreased risk for end-stage renal disease (adjusted hazard ratio: 0.77; CI?=?0.62-0.97; p?=?0.024) and for rapid renal function decline (adjusted odds ratio: 0.63; CI?=?0.43-0.95; p?=?0.032); but glycosuria was not associated with all-cause mortality or cardiovascular events. The results were consistent in the propensity-score matched cohort. Glycosuria is associated with increased fractional excretion of electrolytes and is related to favorable renal outcomes in nondiabetic patients with stage 5 CKD.


PROVIDER: S-EPMC5180243 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3631866 | BioStudies
2017-01-01 | S-EPMC5541796 | BioStudies
2020-01-01 | S-EPMC7340300 | BioStudies
2016-01-01 | S-EPMC4703216 | BioStudies
1000-01-01 | S-EPMC3758787 | BioStudies
2018-01-01 | S-EPMC5899226 | BioStudies
2008-01-01 | S-EPMC2572285 | BioStudies
2019-01-01 | S-EPMC6891811 | BioStudies
1000-01-01 | S-EPMC5266030 | BioStudies
2014-01-01 | S-EPMC3922946 | BioStudies